In this podcast, Cancer.Net Associate Editor Dr. Michael Williams describes lymphoma research advances presented at the American Society of Hematology Annual Meeting.
In this month’s From the Editor’s Desk, Dr. Schapira reviews highlights of 2017 in the world of cancer treatment and care.
Cancer survivor Bryant Wieneke describes his experience receiving immunotherapy to treat metastatic melanoma.
La inmunoterapia ha hecho avances apasionantes en 2015. Dado su potencial, ASCO la nombró el adelanto clínico del año 2016 para el cáncer.
ASCO Annual Meeting 2017: Advances in Immunotherapy for Multiple Myeloma and Mesothelioma, and Targeted Therapies for Non-Small Cell Lung Cancer and HER2-Positive Breast Cancer
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Today’s key research highlights include CAR T-cell therapy for multiple myeloma, immune checkpoint inhibitors for mesothelioma, and targeted therapy advances for non-small cell lung cancer and HER2-positive breast cancer.
At the 2017 Clinical Immuno-Oncology Symposium, new research will be presented on the link between gut bacteria and immunotherapy for melanoma and the impact of tumor location in predicting survival from colorectal cancer.
In this podcast, Dr. Sumanta Pal gives an overview of research that will be shared at the 2017 Genitourinary Cancers Symposium.
The 2017 Clinical Cancer Advances report of the American Society of Clinical Oncology has announced that the Advance of the Year is Immunotherapy 2.0. Why 2.0? Because the role of immunotherapy in cancer care is expanding, and oncologists are learning how to use it more effectively.
Recent FDA approvals for immunotherapy drugs for treating lung cancer are exciting, but there still are many things we need to learn about this new field of cancer treatment. Cancer.Net Associate Editor Jyoti Patel, MD, answers some of the questions that surround lung cancer and immunotherapy, during Lung Cancer Awareness Month.
These studies from the ASCO Annual Meeting show some of the newest thoughts and latest advances in using immunotherapy and targeted therapy to treat bladder, stomach, and lung cancers.